Unknown

Dataset Information

0

Wide Corneal Epithelial Thickness Mapping in Eyes With Topical Antiglaucoma Therapy Using Optical Coherence Tomography.


ABSTRACT:

Purpose

The purpose of this study was to assess the corneal epithelial thickness (CET) of the 9-mm diameter zone in patients treated using topical antiglaucoma medications and to evaluate the factors associated with CET changes.

Methods

Seventy-five patients treated using topical antiglaucoma medications and 65 healthy subjects were included in this cross-sectional study. Each patient completed the Ocular Surface Disease Index (OSDI) questionnaire and underwent examinations including the Schirmer I test, tear breakup time (TBUT), and fluorescein staining. CET mapping of the 9-mm diameter zone was performed using RTVue XR. The CET of the different analyzed zones was compared between groups. The relationship between CET and confounding factors was investigated.

Results

The patient group had a significantly shorter TBUT, shorter Schirmer I test, and greater fluorescein staining than those of the control group (all P < 0.05). The mean CET of patients with glaucoma was significantly lower than that of controls in the central, paracentral, mid-peripheral, and peripheral zones (all P < 0.001). Age affected the CET in the paracentral, mid-peripheral, and peripheral zones (all P < 0.01). The number of medications affected the CET in the central, paracentral, and mid-peripheral zones (all P < 0.05). The duration of treatment affected the CET in the central and peripheral zones (all P < 0.05).

Conclusions

Use of topical IOP-lowering medications leads to epithelial thinning in the 9-mm diameter zone in glaucomatous eyes. Epithelial protection should be considered in older patients and patients treated with multiple medications from the early stages of long-term topical antiglaucoma therapy.

Translational relevance

The 9-mm diameter CET mapping by using widefield optical coherence tomography (OCT) can be a valuable and convenient method to assess the ocular surface damage in patients with topical antiglaucoma therapy.

SUBMITTER: Ye Y 

PROVIDER: S-EPMC8742533 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC3514625 | biostudies-literature
| S-EPMC8914566 | biostudies-literature
| S-EPMC4038409 | biostudies-literature
| S-EPMC4031212 | biostudies-literature
| S-EPMC3684006 | biostudies-literature
| S-EPMC7434708 | biostudies-literature
| S-EPMC4190357 | biostudies-literature
| S-EPMC9269451 | biostudies-literature
| S-EPMC6859831 | biostudies-literature
| S-EPMC2408438 | biostudies-literature